Myopericarditis Associated with the Novavax COVID-19 Vaccine (NVX-CoV2373): A Retrospective Analysis of Individual Case Safety Reports from VigiBase.

Diego Macías Saint-GeronsMaría Teresa IbarzJosé Luis CastroJaume Forés-MartosRafael Tabarés-Seisdedos

Published in: Drugs - real world outcomes (2023)

NVX-CoV2373 vaccine showed a similar increased disproportionality as mRNA vaccines. More evidence from controlled studies is necessary; however, a precautionary approach is warranted. Healthcare professionals should be aware of the potential occurrence of myopericarditis with this new vaccine.

Keyphrases

sars cov
respiratory syndrome coronavirus
coronavirus disease
risk assessment
emergency department